[June 21, 2011]

Cannabis Science Hires Donald Shaxon for the Position of Business Development And Catalyst Xchange Corp for Investor And Capital Awareness Campaigns

Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has hired Donald Shaxon for the position of business development manager along with Catalyst Xchange Corp. ("CXC") for investor and capital market awareness campaigns.

Recently, both, in-house and as a consultant, Mr. Shaxon assisted in raising well over 100 million dollars for companies producing Gold and Silver in Canada and Mexico. Mr. Shaxon has more than 15 years of experience in the investor relations and corporate finance fields. Mr. Shaxon is currently on contract with Catalyst Xchange Corp., a Burlington Ontario, Canada based consulting firm. CXC has several more years of expertise in accessing capital markets, public relations, investor relations and awareness campaigns.

Mr. Shaxon, our newly appointed business development manager at Cannabis Science, had this to say, "I'm very excited to be working with the Cannabis Science team once again, and speaking on behalf of the team at CXC and myself, we've be looking forward to this for some time. We anticipate a great year of assisting Canabis Science in accessing capital markets and building investor awareness and value."

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "Catalyst Xchange Corp has once again been retained to provide assistance in the area of capital market financing and investor marketing for the company. Under the terms of the agreement, a member of the CXC team, Mr. Donald Shaxon, will be appointed business development manager at Cannabis Science Inc. for a term of 12 months."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

www.cannabisscience.com

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

[ Back To TMCnet.com's Homepage ]